EQS-News: Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
|
EQS-News: BRAIN Biotech AG
/ Key word(s): Personnel
Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG ZWINGENBERG, Germany, July 23, 2025 – The Supervisory Board of BRAIN Biotech AG is once again fully staffed: Dr. Ursula La Cognata has been appointed as a new member of the 6-person Supervisory Board by the Darmstadt District Court with effect from July 11, 2025 until the next Annual General Meeting. Her many years of experience in biotechnology will be an important asset in the supervisory board of BRAIN. Dr. Ursula La Cognata has held senior positions in several companies with a strong biotechnology focus, including Aventis and Bayer, most recently with a focus on enzymes, fermentation, and natural food. Dr. La Cognata currently manages her own consulting firm and supports innovative companies in the food sector with new product market launches and the development of production as well as fermentation capacities. Supervisory Board Chairman Dr. Michael Majerus explains: "With Dr. Ursula La Cognata, we have gained a highly competent and experienced biotechnology expert for our Supervisory Board who, in addition to her extensive industry experience in enzymes and fermentation processes, will also contribute her expertise in product development as well as launching innovations. We cordially welcome our new member of the Supervisory Board and look forward to working with her." Adriaan Moelker, CEO of BRAIN Biotech AG, adds: "I’m delighted about the extensive biotechnology expertise of our new Supervisory Board member. With Dr. La Cognata, we are gaining a wealth of experience and network access in our target markets of nutrition, life sciences, and environment." The appointment of a new member to the Supervisory Board has been required after a previous member resigned for personal reasons. +++ BRAIN Biotech Group The BRAIN Biotech Group is a leading company in the research, development and production of specialty enzymes with a focus on the food and life science industries. In addition, the Group develops microbial production organisms and scalable bioprocesses for the economic production of specialty enzymes and other proteins. Customized innovative biological solutions for more sustainable products and processes round off the portfolio. The parent company of the BRAIN Biotech Group is BRAIN Biotech AG. The business activities of the integrated company are divided into the two segments BRAINBiocatalysts (development, production and distribution of specialty enzymes, microorganisms, ingredients) and BRAINBioIncubator (research-intensive development projects, pharmaceuticals). For production, the Group operates fermentation plants in the UK as well as production facilities in continental Europe and the USA. BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 300 people at several locations and generated revenues of EUR 54.6 million in the 2023/24 financial year. Further information can be found at: www.brain-biotech-group.com.
Contact Investor Relations Martina Schuster
Contact Media Dr. Stephanie Konle
The BRAIN Biotech Group on social media and on the internet: BRAIN Biotech Group Web: www.brain-biotech-group.com LinkedIn: https://www.linkedin.com/company/brainbiotech Threads: https://www.threads.net/@brainbiotechag Bluesky: https://bsky.app/profile/brain-biotech-group.com Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg
Biocatalysts Ltd (Production, Sales) Web: https:/www.biocatalysts.com LinkedIn: Biocatalysts Ltd on LinkedIn
BRAIN Biotech Zwingenberg (Research & Development) LinkedIn: https://www.linkedin.com/showcase/brain-biotech-research-and-development/
AnalyticonDiscovery (Research & Development) Web: https://ac-discovery.com/
Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.
23.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | BRAIN Biotech AG |
| Darmstädter Straße 34-36 | |
| 64673 Zwingenberg | |
| Germany | |
| Phone: | +49 (0) 62 51 / 9331-0 |
| Fax: | +49 (0) 62 51 / 9331-11 |
| E-mail: | ir@brain-biotech.com |
| Internet: | www.brain-biotech.com |
| ISIN: | DE0005203947 |
| WKN: | 520394 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2173240 |
| End of News | EQS News Service |
|
|
2173240 23.07.2025 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
| Die wichtigsten Finanzdaten auf einen Blick | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Umsatzerlöse1 | 38,56 | 38,23 | 38,39 | 45,51 | 55,34 | 54,63 | 62,50 | |
| EBITDA1,2 | -2,50 | -3,88 | -2,53 | -1,31 | -0,83 | -4,03 | -1,00 | |
| EBITDA-Marge3 | -6,48 | -10,15 | -6,59 | -2,88 | -1,50 | -7,38 | -1,60 | |
| EBIT1,4 | -7,20 | -8,23 | -6,55 | -5,65 | -5,48 | -8,85 | -3,50 | |
| EBIT-Marge5 | -18,67 | -21,53 | -17,06 | -12,42 | -9,90 | -16,20 | -5,60 | |
| Jahresüberschuss1 | -11,12 | -9,02 | -4,68 | -6,34 | -8,11 | -11,10 | -5,80 | |
| Netto-Marge6 | -28,84 | -23,59 | -12,19 | -13,93 | -14,66 | -20,32 | -9,28 | |
| Cashflow1,7 | -3,38 | -4,77 | -3,10 | -1,49 | -4,22 | -3,58 | -1,15 | |
| Ergebnis je Aktie8 | -0,61 | -0,52 | -0,25 | -0,30 | -0,38 | -0,51 | -0,26 | |
| Dividende8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Baker Tilly
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
| INVESTOR-INFORMATIONEN | ||||||
| ©boersengefluester.de | ||||||
| BRAIN Biotech | ||||||
| WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
| 520394 | DE0005203947 | AG | 66,20 Mio € | 09.02.2016 | Halten | 8FXCPJH6+57 |
| KGV 2026e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
| 23,31 | 0,00 | 0,00 | -6,27 | 13,42 | -18,48 | 1,21 |
|
Dividende '2023 in € |
Dividende '2024 in € |
Dividende '2025e in € |
Div.-Rendite '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
| 11.03.2026 | 25.02.2026 | 28.05.2026 | 28.08.2025 | 14.01.2026 |
| Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
| +24,18% | +34,07% | -14,65% | -20,89% | -66,33% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.
Kontakt
